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Introduction
What is the value of medical research? The question initially provokes an ethical
response: the worth of a clinical trial is generally understood in terms of the impact of its
outcomes on patient populations. The evaluation of human subjects research raises
normative questions of values  the future well-being of society in relation to the risk
experimental procedures entail for participants. However, biomedical facts also circulate
within national systems of healthcare, global policy organizations, property regimes and
pharmaceutical markets. The current dominance of public-private partnerships under the
rubric of ‘global health’, the uptake of pro-market strategies by governmental and
philanthropic organizations, the bankrolling of the WHO by private individuals, suggest
the extent to which the value of both therapeutic products and public health practices
have been appropriated by a logic of profit. Clinical trials engage with and generate
multiple orders of value; they straddle the world of commodities and public goods, of
fiscal costs and moral virtues (Stark 2009).
The papers in this special issue probe the different systems of value that exist
between scientific ends, public goods, and lucrative commodities. Taking inspiration from
recent ethnographic studies of finance in practice (e.g. Roitman 2005) and economic
sociology (e.g. C ¸alıs ¸kan & Callon 2009), they explore how value is variously worked
through material, socio-technical relations, institutions, and research practice. To discern
the value of research ethnographically, a common starting point of these papers is the
work of medical research, including volunteered participation, contracted employment,
scientific analysis or ethical oversight. In drawing attention to the modalities of intellectual,
practical, and affective labour that drive a clinical trial, this special issue situates the
production of medical knowledge with respect to other forms of productive activity. In so
doing, we seek to nuance perspectives on the significance of clinical research to the
welfare of societies.
What follows is a selective overview of social scientific research that explores the
linkages between clinical trials, pharmaceutical markets and global health inequities. We
suggest that this scholarship can be roughly characterized by two distinct critical aims. The
first concerns the political economy of medical research and the structural conditions
under which health becomes a resource for wealth. The value of medical research is
analysed through an investigation of medical markets as networks of knowledge
production, therapeutic consumption, and capital accumulation. The second interrogates
the ethical significance of transnational clinical experimentation. In these studies, value is
elaborated as a negotiation between the interests of communities, the protocols of
science, the priorities of global health; it indicates access to life saving therapies, the
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Though articulated in different registers, we suggest that both these approaches to
value demarcate the ‘social’ from the ‘economic’ dimensions of clinical research. Studies
that explore the sociological consequences of the commercialization of medical research
and those that seek to strengthen the moral traction of experimental procedures both
analyse value as a structuring and systematic logic. We take an alternative track.
Concerned with how the material practices of medical research intersect with everyday
ways of living, we propose a more promiscuous approach to the question of value, one
that is acutely aware of the diverse valuable materials and manifold processes of valuation
attendant to medical experimentation. The purpose of drawing upon categories of value
theory, such as ‘labour’, ‘production’, and ‘circulation’, is to open up these variables to
ethnographic scrutiny (Graeber 2001). Rather than warn against economic incursions into
medical knowledge and health practice, or, alternatively, the reduction of local experience
to the standards of bioethics, we hope to illuminate the array of practices, knowledges,
and techniques through which the value of medical research is brought into being.
Political Economy of Clinical Research
The financial resources and scale of operations of contemporary pharmaceutical
research have laid bare the contradictions between the economic and therapeutic value of
biomedical production. The multi-billion dollar quest for new pharmaceutical products
reveals the strange alchemy whereby marginalized populations in desperate need of
healthcare come to sustain the research efforts of an industry dedicated to the needs of
affluent populations. For the most part, the social sciences have explored these conflicts
by examining the institutional contexts of research, such as regulatory and intellectual
property arrangements, and tracing the public health contours of the pharmaceutical
industry’s transnational reach. These investigations consider the clinical trial as the
dominant mode of medical knowledge production and analyse its value in relation to
capitalist system of commodity production.
The rise of the pharmaceutical industry hinges upon the standardization of an
evaluative method, the randomized control trial (RCT). The RCT provides a statistical
framework to interpret the merits of new drugs against the biases of patients and doctors.
As Marks (1997) notes, though the method can be understood as part of a general
epistemic shift across the sciences to practices that privilege objectivity and disinterest-
edness, the particular objectivity of the RCT is defined by the needs of the market place.
Clinical trials not only enabled consumers to distinguish between the medicine and snake
oil but also, by testing novel products on large group of patients, allowed drugs to be
produced on an industrial scale.
The soaring costs of pharmaceutical research and development have amplified the
tension between the methodological purposes of the RCT and its pragmatic orientation as
a marketing device. Sociological attention to the marketing of pharmaceuticals has
revealed the range of industry tactics used to boost sales, such as financing disease
awareness campaigns, ghost-writing scientific articles, developing partnerships with
leading medical professionals, and even, auditing physicians’ prescription practices
(Sismondo 2009). However, these efforts are secondary to the need to persuade regulatory
agencies of a drug’s efficacy. That pressure to gain approval has increased the number of
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is the ever more common practice of assuring the efficacy of experimental entities through
the selection of homogeneous patient populations, the exclusion of ‘placebo-responders’,
statistically massaging data and concealing negative outcomes (Lakoff 2005).
The first conclusion of these studies is that industry-sponsored clinical trials often fail
to generate innovative, or indeed necessary, therapies. The second is that, owing to the
clandestine nature of privatized science, clinical trials do not necessarily produce valid
scientific information. Appropriated by commercial imperatives, the clinical trial is regularly
reduced to what Michael Power describes as a ritual verification  a technique to produce
public confidence in the absence of empirical content (Power 1994). Their primary purpose
is to provide an interface between the industry and practitioners, widening a prescribing
base to introduce experimental entities into circulation. In-depth investigations of
regulatory decision-making practices have further illuminated the government’s compli-
city in permitting risky and ineffectual products into the market place (McGoey 2007). The
interpenetration of private and public institutions has reconfigured the standards of
regulatory science around the commercial interests of the drug manufacturer as opposed
to the interests of patients.
The second critical argument is that the global proliferation of pharmaceuticals has
reconfigured the economic value of health. As possible consumers of therapies, patients
are exploited for their ‘surplus health’; their healthiness provides not the basis for a
workforce but rather for pharmaceutical capital (Sunder Rajan 2002). The abstraction of
the patient’s well-being into a commodity form is made possible through the exploitation
of the experimental subject. Petryna’s (2009) analysis of the outsourcing of clinical trials to
contract research organizations (CROs) makes this point clear by showing how situations
of health crisis offer opportunities for pharmaceutical companies to circumvent regulatory
systems and gain access to research subjects whose lack of education, financial resources
or treatment history makes them more likely to produce ‘cleaner results’. The redistribu-
tion of biomedical risk tracks other forms of ‘flexible’ industrial production, with its
increasing reliance on insecure, casual labour, decentralized governance and the resulting
accentuation of North-South inequalities.
These accounts of ‘neoliberal science’ derive from pertinent observations of a
capitalist economy, marked by the enclosure of the scientific commons, institutional
restructuring and restrictive intellectual property regulations. Ultimately, they:
reveal an emerging ‘values gap’. Its symptoms include the growing division between
populations that have access to life-saving drugs and the ability to pay for them, and
populations that have neither and must rely on some other form of distribution ...
human experiences of suffering and its costs of ‘morbidity’ and other indicators
configuring social need. (Petryna & Kleinman 2005, p. 6)
Value, in these studies, indexes a scandal  the incommensurability between the
calculative logic of profit-maximization and the needs of populations.
Clinical Research Ethics
The second branch of the literature relevant for this special issue elaborates the
value of transnational clinical research within an ethical framework. Though, in practice,
the backbone of biomedical ethics continues to be informed consent  a rubric that seeks
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focuses academic debate. In these discussions, value adds specificity the abstract notion of
public good. The idiom of value allows ethicists to raise the questions of good for whom, in
what form, and critically, at what point; social value speaks to the immediate and concrete
benefits associated with the conduct of medical research, such as jobs, training, and
health-care services.
Like the sociological work discussed above, the shift in ethical discourse towards a
theory of value reflects a concern with changes in the relationship between medical
science, industry and public health, and increased attention to vital inequalities within
the production of scientific knowledge. The concern here is less directly with the
commercialization of science  though the discrepancy between the priorities of industry-
sponsored research and global health burden has been widely acknowledged. Rather
what is at stake is the gap between experimental outcomes and improvements in health
practice, particularly where weak infrastructure prevents research findings from being
translated into health practices: between what is possible for those in control of medical
research, and what is needed by those who lend their bodies to it.
The Randomized Controlled Clinical Trial (RCT) is a distributive device; the initial
justification for the randomization of treatment was to ensure the fair allocation of
medicines in short supply. Clinical science and the management of public health are,
therefore, intimately connected. The dominance of public private partnerships and the
slimming of state-sponsored research, compounded by the collapse of public health
institutions and health services, most notably in many eastern European and African
nations, have made that connection increasingly tenuous. While big charity and private
partnerships often tackle issues of particular relevance for poorer populations, unable to
attract enough profit-orientated funding from the pharmaceutical industry, experiments
are usually conducted in the absence of significant government incentives, and rarely
engender any public health interventions beyond ‘policy advice’.
In settings where healthcare is often a matter of international and non-governmental
intervention, a ‘social value’ framework addresses the fragile links between research, policy,
and practice. One important way in which value can be ‘added’ is by ensuring benefits are
in place after the conclusion of trials, for instance, through the dissemination of results, the
provision of continued access to therapies or the building of ‘capacity’. These measures to
entangle the experiment in local clinical contexts represent a shift ethical doctrine towards
the empirical, and give precedence to social scientific explorations into community
perspectives, traditions, and social practices. Recent scholarship on how communities make
sense of research (Geissler & Molyneux 2010) and the centrality of ‘trust’ in community-
research relations (Gikonyo et al. 2008) has further pressed ethical discussion beyond what
might be added to existing projects, to consider the ways in which local participants
might shape the research design. In this sense, the generation of social value has been
increasingly tied to mechanisms of ‘public consultation’, ‘community partnership’,o r
‘collaborator networks’ that attempt to:
involve partners in sharing responsibilities for determining the importance of health
problem, assessing the value of research, planning, conducting, and overseeing research,
and integrating research into the health-care system. (Emanuel et al. 2004, p. 931)
The collectivization of experimental subjects and their transformation into empowered
publics has emerged as a salient model in western research contexts. Epstein’s (1996) now
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clinical trials can provide an interface for lay citizens to impact the orientation,
management, and evaluation of medical research. A method whose scientific integrity
depends on the representative character of the sample, the clinical trial is also a political
resource; it offers occasions for new approaches to the production of knowledge and
value that rest on the dynamic collaboration of civil society.
Less sanguine accounts regard these efforts to elicit a ‘public voice’ as a way of
displacing local politics. Hayden’s (2007) analysis of benefit-sharing agreements offered by
bioprospecting firms, for instance, points to how practices of participation strategically
fragment publics into those that can legitimate and facilitate the collections of resources
and those that cannot. In the cases she describes, value is not distributed to existing social
groups, but rather collectives are configured around the interests of the industry. Other
scholars have linked the anti-politics of community-engagement to the emergence of
stateless forms of citizenship. In contrast to policy initiatives that emphasize the provision
of health services, these critiques suggest that the entanglement of clinical research with
the development industry has conflated participation in trials with participatory
governance and civic life with therapeutic access (e.g. Nguyen 2005).
Informed by long-term ethnographic engagements with developing world contexts,
these critiques remain sceptical of the ability of bioethical inquiry to advance the
redistribution of value. However, despite the efforts to address differentials in wealth and
power, these studies remain grounded in the specific histories of biomedical research and
administrative practice, and committed to the democratic possibilities of that relationship.
The idiom of social value preserves a domain of clinical research where normative
questions of accountability, representation, publics, and of values can be raised.
Value at Work
Considered together, these discussions highlight the two dimensions of the value of
clinical trials  one defined by the market valuation of medical commodities and the other
characterized by population welfare. Though they draw from distinct empirical material,
these two lines of critique share the central premise that the normative and sociological
questions of medical research should be held distinct from economic analysis. The papers
presented at the workshop from which this special issue derives were given with the
intention of transcending dichotomies between the economic and the moral by fostering
dialogue with health policy, medical researchers, and patient activists and engendering a
more honest consideration of the politics, economics, and pragmatics of conducting
clinical trials than those provided by bioethics. In situating the value of clinical research
ethnographically, that is by examining the material activities and semiotic forms through
which it is mediated, the contributors take inspiration from a Marxian theory of value (e.g.
Turner 2008), but refrain from grounding clinical research value in a single circuit of
production. Rather they pursue what is perhaps best understood as the ‘material politics’
(Law & Mol 2008) of clinical trials  how, in other words, research value is multiply
configured in therapeutic, social, and economic landscapes. In following these terrains,
contributors materialize value in relationship with, rather than in opposition to, values
(Miller 2007).
Catherine M. Will’s analysis of UK research policy describes the strategic distribution
of medical research value through the conduct of clinical trials. Over the past decade, the
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advantageous site for industry-sponsored research. Will interrogates the ‘multiplication of
value’ these trials are expected to bring by tracking the formal and informal ways in which
patient benefit isconstituted. Inparticular, she attends tothespaces  the curtains cubicles,
Victorian windows and impromptu breakfast tables  where experimental protocols and
clinical care, individual health and commercial profit ‘come together in more or less
awkward juxtapositions’. Will supports these compelling descriptions of the uncanny
atmospheres of clinical research with accounts of the everyday work of carrying out trials,
reflecting on how the therapeutic relationship is managed through distributions of clinical
practice, research protocols, and expressions of hospitality. She suggests that value
multiplies in the moments when these elements come together, and experimental subjects
are afforded additional care than that provided by a researcher, or arguably, the NHS.
One central observation of Will’s chapter is that appeals to clinical research value cut
across different imaginaries of collective and individual benefit. As the UK’s share of
pharmaceutical research increases, the boundary between the research and the clinic
becomes more convoluted, and the risks and impacts of research harder to trace. In his
account of ‘Kurtis Pharmaceuticals’ and ‘Williams Pharmaceuticals’ drug donation
programs in West Africa, Ari Samsky extends Will’s concern with the rhetoric of ‘mutual
benefit’ to the provision of drugs to control river blindness (onchocerciasis), a now high-
profile, ‘Neglected Tropical Disease’. Samsky’s analysis relocates industry practices within a
gift economy, juxtaposing the expectations of the medical-scientific architects of the
donation programs with the disappointments of the Tanzanian farmers receiving the drug.
Like Will, Samsky explores the concrete practices through which research value links
corporate boardrooms to rural African villages. Samsky situates the work of drug
distribution  obscured by the rhetoric of the gift  within the local labour system. His
ethnographic task evokes further questions about the contradictions that underpin Big
Pharma’s efforts to demonstrate corporate responsibility. Together, Will and Samsky
convey the networks of responsibility that characterize pharmaceutical research and
highlight the points at which obligations are cut. Resisting the temptation to read the
dominance of Big Pharma in scientific research as reducing the value of knowledge to
logic of profit, Will and Samsky demonstrate the interference of different value-producing
activities and the hidden costs these entanglements entail.
For P. Wenzel Geissler, it is precisely the invisibility  or rather, unintelligibility  of
material exchanges in the context of the experimental activity that is of interest. Geissler
analyses what would seem a particularly trivial evidence of clinical research value: small
monetary payments, so called ‘transport reimbursements’, made by transnational public
health research organizations to research subjects undergoing clinical procedures,
providing information or biological specimens, or contributing in other ways to scientific
production. From ethnographic work with an HIV trial in western Kenya, Geissler argues
that these small reimbursements are generally understood as a transfer of value (rather
than zero-sum ‘reimbursement’). Though central to research work, these transactions are
obviated by bioethics, which remains focused on the value of individual autonomy and
regards exchanges across extreme economic disparity as potentially violent and coercive.
This ‘unknowing’ of material value in the everyday conduct of scientific production is at
best confusing and possibly politically problematic. But rather than embrace a unitary
model of exchange to replace the bioethical insistence on giving, Geissler’s stresses the
complex interplay of value these vital transactions entail  reimbursements not only
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belonging and the promise of care. The calculative logic is embedded in the conviviality of
trial relations; the ‘gift’, he reminds us, has never been free.
The connection between the individual activities and collective imaginaries of
research is an analytical concern Ann H. Kelly shares. Her paper focuses on a malaria
control trial in Dar es Salaam and interrogates the scientific, political, and economic
significance of the pain-staking work of monitoring the movements of mosquitoes. Kelly’s
analysis begins from the collective body of voluntary mosquito collectors and the ways in
which that collective is inter-articulated by the protocols of scientific research, the post-
socialist politics of Tanzania and the economics of global health. She is particularly drawn
to the presence of these workers  fixed points in the inter-circulations of capital, fact, and
disease. Kelly contrasts this immobile work to the fluid and sporadic modes of productivity
engendered by the experimental project. Her ethnography illustrates how the former
anchors the latter, linking scientific research to social progress.
Finally, Melinda Cooper reads the development of the large-scale clinical trial against
the organizational logic of Fordist industrial production, a genealogy that reframes the
risks entailed by the human subject as consistent with those belonging to the industrial
workplace and underwritten by the welfare state. In light of her analysis, informed
consent, stripped of any of the broader protections afforded to a worker who might fall
and suffer an industrial accident, seems a rather flimsy form of protection for the
experimental subject. However, like Geissler, Cooper is not convinced that the labour
model offers much in the way of an alternative  the standard wage for unskilled labourers
is, in fact, much lower than the compensations received by the average trial subjects, at
least in the North. Instead, the connections Cooper draws between the history of the
clinical trial and that of labour reforms, reveals the constitutive role of the clinical trial in
conceptualizing the public. Cooper argues that the welfare state was subtended by
actuarial logic  welfare could only provided once it was capable of calculating the
effectives of interventions on the populace. The clinical trial made this calculation possible,
by subjecting the few to the accidents of the experiment. As opposed to the uniform
national collective imagined by Titmuss (1970), Cooper exposes the forms of margin-
alization that create the conditions for a coherent social body.
Like other contributors in this special issue, Cooper explores the ways in which the
research value is shaped by governmental rationality and generates new languages of
contestation. Should volunteers in research be compensated in the same ways that local
fieldworkers are paid to gather data? What are the terms of collaboration between health
researchers, governments, and free enterprise? How is research value best pursued, by
securing health, reducing inequality, growing the economy or sustaining employment?
This special issue raises these questions through an exploration of how research is actually
done  the practical alignments of institutions, actors, resources, objects, and interests.
These empirical engagements with the intersection of values and values will provide, we
hope, new conceptual resources to guide ethical and social scientific inquiries into the
links between science and the public good.
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